Enliven Therapeutics, Inc. (NASDAQ:ELVN)
| Market Cap | 3.04B+94.0% |
| Revenue (ttm) | 0 |
| Net Income | -105.93M-5.7% |
| EPS | -1.64+18.0% |
| Shares Out | 73.27M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 2,298,502 |
| Open | 41.49 |
| Previous Close | 41.93 |
| Day's Range | 40.65 - 41.64 |
| 52-Week Range | 14.79 - 62.32 |
| Beta | 0.24 |
| Analysts | Buy |
| Price Target | 76.29(+83.74%) |
| Earnings Date | Nov 11, 2026 |
Insiders filed in the last 90 days, but none of those trades qualified for scoring — round-trip buys and filings whose price is far off the market are excluded.
About ELVN
Enliven Therapeutics, Inc. is a biopharmaceutical enterprise, currently in the clinical development phase, dedicated to discovering and advancing small molecule therapeutic agents aimed at combating cancer. Its pipeline includes ELVN-001, a small molecule kinase inhibitor currently in a Phase 1 clinical trial for adult patients with chronic myeloid leukemia. Another key candidate, ELVN-002, also a small molecule kinase inhibitor, has begun a Phase 1 clinical assessment for individuals with cancers exhibiting an abnormal HER2 gene. The company's base of operations is located in Boulder, Colorado.
What Are Insiders Doing?
View the trades behind this meter — each links to its SEC Form 4 →
Open-market Form 4 purchases (code P) vs sales (code S) on file for this company. Grants, option exercises and tax withholdings are excluded. Informational only.
$ELVN stock is featured in our Insider Score Rankings, and Insider Trades datasets.
→ All Stock ListsRecently reported changes in ELVN holdings by institutional investors
Latest 0 13F filings · Source: SEC EDGAR
View all institutional owners →Insider Trading
Quarterly net insider trading by ELVN's directors and management
Source: SEC EDGAR (Form 4)
Corporate Lobbying
ELVN Estimated quarterly lobbying spending
Source: U.S. Senate LDA
ELVN Revenue by Segment
| Segment | Revenue | % of All |
|---|---|---|
| Stock-based compensation | $9.36M | 39.70% |
| ELVN-001 | $8.31M | 35.25% |
| Other | $4.03M | 17.10% |
| ELVN-002 | $1.23M | 5.22% |
| Facilities, laboratory supplies and other | $643.00K | 2.73% |
As of: Q2 2026 (Jun 30, 2026) · Source: SEC EDGAR (10-Q)
U.S. Patents
New ELVN patent grants
Source: USPTO Open Data Portal
Government Contracts
Estimated quarterly amount awarded to ELVN from public contracts
Source: USAspending.gov
Top ETF Holders
ETFs with the largest estimated holdings in ELVN
| ETF | Est. Holding Size |
|---|---|
| IWMiShares Russell 2000 ETF | $61.27M |
| IWOiShares Russell 2000 Growth ETF | $22.80M |
| IBBiShares Biotechnology ETF | $19.41M |
| VTWOVanguard Russell 2000 ETF | $15.52M |
| DFASDimensional - US Small Cap ETF | $14.81M |
| SCHASchwab U.S. Small-Cap ETF | $14.08M |
Estimated from each fund’s disclosed top holdings × AUM
ELVN Insider Score
Our composite score: insider buying, sector, volume, tone & dilution
Bull Case vs Bear Case
AI-generated from ELVN’s recent data — informational, not investment advice
Insider Score
Our 0–100 Insider Score and the signals behind it.
The live Insider Score and its full factor breakdown are included with Insider Access.
Unlock Insider Score